nach oben

Breast Cancer Research and Treatment

Erschienen in:

23.06.2020 | Review

Impact of NR5A2 and RYR2 3′UTR polymorphisms on the risk of breast cancer in a Chinese Han population

verfasst von: Ying Wei, Xiaolin Wang, Zhe Zhang, Changtao Zhao, Yuwei Chang, Zhiqing Bian, Xinhan Zhao

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The NR5A2 and RYR2 genes are important players in steroid metabolism and play an important role in cancer research. In this research, we want to evaluate the effect of NR5A2 and RYR2 polymorphisms on breast cancer (BC).

Methods

Four single nucleotide polymorphisms on NR5A2 and RYR2 were selected to genotype by Agena MassARRAY in 379 BC patients and 407 healthy controls. Using the PLINK software to calculate the Odds ratio (OR) and 95% confidence intervals (CIs) via the logistic regression analysis to evaluate the risk for BC.

Results

We found that NR5A2 rs2246209 significantly decreased the risk of BC with the AA genotype (OR 0.58, 95%CI 0.34–0.99, p = 0.049), and recessive model (OR 0.59, 95%CI 0.35–0.99, p = 0.046); rs12594 in the RYR2 gene significantly decreased the risk of BC in the GG genotype (OR 0.44, 95%CI 0.22–0.88, p = 0.020), and recessive model (OR 0.43, 95%CI 0.21–0.85, p = 0.016). Further stratification analysis showed that NR5A2 rs2246209 was related to a lower incidence of BC affected by age, lymph nodes metastasis, and tumor stage; RYR2 rs12594 was related to a decreased BC risk restricted by age, estrogen receptor (ER), progesterone receptor (PR), menopausal status, tumor size, and tumor stage. Rs12594 in the RyR2 gene remained significant on the genetic susceptibility of PR-positive BC after Bonferroni correction (p < 0.0125).

Conclusions

This study provides an evidence that NR5A2 rs2246209 and RYR2 rs12594 decreased the risk of breast cancer.

Pontikaki A, Sifakis S, Spandidos DA (2016) Endometriosis and breast cancer: a survey of the epidemiological studies. Oncol Lett 11(1):23–30PubMed

Li N, Deng Y, Zhou L, Tian T, Yang S, Wu Y, Zheng Y, Zhai Z, Hao Q, Song D et al (2019) Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study. J Hematol Oncol 12(1):140PubMedPubMedCentral

Deng Z, Yang H, Liu Q, Wang Z, Feng T, Ouyang Y, Jin T, Ren H (2016) Identification of novel susceptibility markers for the risk of overall breast cancer as well as subtypes defined by hormone receptor status in the Chinese population. J Hum Genet 61(12):1027–1034PubMed

Singh K, He X, Kalife ET, Ehdaivand S, Wang Y, Sung CJ (2018) Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results. Breast Cancer Res Treat 168(1):29–34PubMed

Dai ZJ, Liu XH, Ma YF, Kang HF, Jin TB, Dai ZM, Guan HT, Wang M, Liu K, Dai C et al (2016) Association between single nucleotide polymorphisms in DNA polymerase kappa gene and breast cancer risk in Chinese Han population: a STROBE-Compliant Observational Study. Medicine (Baltimore) 95(2):e2466

Wang S, Zou Z, Luo X, Mi Y, Chang H, Xing D (2018) LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer. Oncogene 37(24):3243–3259PubMed

Chand AL, Wijayakumara DD, Knower KC, Herridge KA, Howard TL, Lazarus KA, Clyne CD (2012) The orphan nuclear receptor LRH-1 and ERα activate GREB1 expression to induce breast cancer cell proliferation. PLoS ONE 7(2):e31593PubMedPubMedCentral

Fernandez-Marcos PJ, Auwerx J, Schoonjans K (2011) Emerging actions of the nuclear receptor LRH-1 in the gut. Biochim Biophys Acta 1812(8):947–955PubMed

Huang SC, Lee CT, Chung BC (2014) Tumor necrosis factor suppresses NR5A2 activity and intestinal glucocorticoid synthesis to sustain chronic colitis. Sci Signal 7(314):ra20PubMed

10.

Sahini N, Borlak J (2016) Genomics of human fatty liver disease reveal mechanistically linked lipid droplet-associated gene regulations in bland steatosis and nonalcoholic steatohepatitis. Transl Res 177:41–69PubMed

11.

Ueno M, Ohkawa S, Morimoto M, Ishii H, Matsuyama M, Kuruma S, Egawa N, Nakao H, Mori M, Matsuo K et al (2015) Genome-wide association study-identified SNPs (rs3790844, rs3790843) in the NR5A2 gene and risk of pancreatic cancer in Japanese. Sci Rep 5:17018PubMedPubMedCentral

12.

Zhang X, Gu D, Du M, Wang M, Cao C, Shen L, Kuang M, Tan Y, Huo X, Gong W et al (2014) Associations of NR5A2 gene polymorphisms with the clinicopathological characteristics and survival of gastric cancer. Int J Mol Sci 15(12):22902–22917PubMedPubMedCentral

13.

Xiao L, Wang Y, Liang W, Liu L, Pan N, Deng H, Li L, Zou C, Chan FL, Zhou Y (2018) LRH-1 drives hepatocellular carcinoma partially through induction of c-myc and cyclin E1, and suppression of p21. Cancer Manag Res 10:2389–2400PubMedPubMedCentral

14.

Chang LY, Liu LY, Roth DA, Kuo WH, Hwa HL, Chang KJ, Hsieh FJ (2015) The major prognostic features of nuclear receptor NR5A2 in infiltrating ductal breast carcinomas. Int J Genomics 2015:403576PubMedPubMedCentral

15.

Laver DR (2018) Regulation of the RyR channel gating by Ca(2+) and Mg(2). Biophys Rev 10(4):1087–1095PubMedPubMedCentral

16.

Ogawa Y (1994) Role of ryanodine receptors. Crit Rev Biochem Mol Biol 29(4):229–274PubMed

17.

Femi OF (2018) Genetic alterations and PIK3CA gene mutations and amplifications analysis in cervical cancer by racial groups in the United States. Int J Health Sci (Qassim) 12(1):28–32

18.

Cai W, Zhou D, Wu W, Tan WL, Wang J, Zhou C, Lou Y (2018) MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. BMC Genomics 19(1):582PubMedPubMedCentral

19.

Abdul M, Ramlal S, Hoosein N (2008) Ryanodine receptor expression correlates with tumor grade in breast cancer. Pathol Oncol Res : POR 14(2):157–160PubMed

20.

Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu H, Liu P, Hao X, Zhang W, Chen K (2011) Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci USA 108(33):13653–13658PubMed

21.

Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES (2001) High-resolution haplotype structure in the human genome. Nat Genet 29(2):229–232PubMed

22.

Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M et al (2002) The structure of haplotype blocks in the human genome. Science (New York, NY) 296(5576):2225–2229

23.

Patil N, Berno AJ, Hinds DA, Barrett WA, Doshi JM, Hacker CR, Kautzer CR, Lee DH, Marjoribanks C, McDonough DP et al (2001) Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science (New York, NY) 294(5547):1719–1723

24.

Chen Q, Sun Y, Wu J, Xiong Z, Niu F, Jin T, Zhao Q (2019) LPP and RYR2 Gene polymorphisms correlate with the risk and the prognosis of astrocytoma. J Mol Neurosci : MN 69(4):628–635PubMed

25.

Zhou L, Dong S, Deng Y, Yang P, Zheng Y, Yao L, Zhang M, Yang S, Wu Y, Zhai Z et al (2019) GOLGA7 rs11337, a polymorphism at the microRNA binding site, is associated with glioma prognosis. Mol Ther Nucleic Acids 18:56–65PubMedPubMedCentral

26.

Deng Y, Zhou L, Li N, Wang M, Yao L, Dong S, Zhang M, Yang P, Hao Q, Wu Y et al (2019) Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: a case-control study. Mol Carcinog 58(12):2218–2229PubMed

27.

Wang J, Shi Y, Wang G, Dong S, Yang D, Zuo X (2019) The association between interleukin-1 polymorphisms and their protein expression in Chinese Han patients with breast cancer. Mol Genet Genomic Med 7:e804PubMedPubMedCentral

28.

Adamec C (1964) Example of the use of the nonparametric test. Test X2 for comparison of 2 independent examples. Ceskoslovenske zdravotnictvi 12:613–619PubMed

29.

Bland JM, Altman DG (2000) Statistics notes. The odds ratio. BMJ (Clin Res ed) 320(7247):1468

30.

Christopoulos PF, Corthay A, Koutsilieris M (2018) Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics. Cancer Treat Rev 63:79–95PubMed

31.

Garattini E, Bolis M, Gianni M, Paroni G, Fratelli M, Terao M (2016) Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer. Oncotarget 7(27):42661–42682PubMedPubMedCentral

32.

Nadolny C, Dong X (2015) Liver receptor homolog-1 (LRH-1): a potential therapeutic target for cancer. Cancer Biol Ther 16(7):997–1004PubMedPubMedCentral

33.

Zhu J, Zou Z, Nie P, Kou X, Wu B, Wang S, Song Z, He J (2016) Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Cell Death Dis 7(11):e2454PubMedPubMedCentral

34.

Pang JB, Molania R, Chand A, Knower K, Takano EA, Byrne DJ, Mikeska T, Millar EKA, Lee CS, O'Toole SA et al (2017) LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. Oncotarget 8(48):83626–83636PubMedPubMedCentral

35.

Bianco S, Brunelle M, Jangal M, Magnani L, Gevry N (2014) LRH-1 governs vital transcriptional programs in endocrine-sensitive and -resistant breast cancer cells. Cancer Res 74(7):2015–2025PubMed

36.

Kobylewski SE, Henderson KA, Eckhert CD (2012) Identification of ryanodine receptor isoforms in prostate DU-145, LNCaP, and PWR-1E cells. Biochem Biophys Res Commun 425(2):431–435PubMed

37.

Davis FM, Parsonage MT, Cabot PJ, Parat MO, Thompson EW, Roberts-Thomson SJ, Monteith GR (2013) Assessment of gene expression of intracellular calcium channels, pumps and exchangers with epidermal growth factor-induced epithelial-mesenchymal transition in a breast cancer cell line. Cancer Cell Int 13(1):76PubMedPubMedCentral

38.

Perneger TV (1998) What's wrong with Bonferroni adjustments. BMJ 316(7139):1236–1238PubMedPubMedCentral

39.

Huang W, Nie W, Zhang W, Wang Y, Zhu A, Guan X (2016) The expression status of TRX, AR, and cyclin D1 correlates with clinicopathological characteristics and ER status in breast cancer. Onco Targets Ther 9:4377–4385PubMedPubMedCentral

40.

Hilton HN, Clarke CL, Graham JD (2018) Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Mol Cell Endocrinol 466:2–14PubMed

41.

Wang B, Yuan F (2018) Comment on "Estrogen receptor alpha (ERS1) SNPs c454–397T>C (PvuII) and c454–351A>G (XbaI) are risk biomarkers for breast cancer development". Mol Biol Rep 46:5PubMed

42.

Suba Z (2014) Diverse pathomechanisms leading to the breakdown of cellular estrogen surveillance and breast cancer development: new therapeutic strategies. Drug Des Devel Ther 8:1381–1390PubMedPubMedCentral

Titel: Impact of NR5A2 and RYR2 3′UTR polymorphisms on the risk of breast cancer in a Chinese Han population
verfasst von: Ying Wei
Xiaolin Wang
Zhe Zhang
Changtao Zhao
Yuwei Chang
Zhiqing Bian
Xinhan Zhao
Publikationsdatum: 23.06.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05736-w

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Impact of NR5A2 and RYR2 3′UTR polymorphisms on the risk of breast cancer in a Chinese Han population

Abstract

Objectives

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management

High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer

Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score

Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer

Cardiovascular mortality and morbidity burden in successive and age pre-stratified case–control cohorts of breast cancer women. A population-based study

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie